TY - JOUR
T1 - Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia (Protocol)
AU - Taylor-Rowan, Martin
AU - Kraia, Olga
AU - Kolliopoulou, Christina
AU - Cross, Amanda J.
AU - Stewart, Carrie
AU - Myint, Phyo K.
AU - McCleery, Jenny
AU - Quinn, Terry J.
N1 - Funding Information:
This protocol was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health.
Funding Information:
We will follow best practice in design, conduct, and reporting of our prognosis review as detailed in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2019). The review will be supported by the Cochrane Prognostic Methods Group, partners within the Cochrane Mental Health and Neuroscience Network, and the UK National Institute for Health Research Complex Reviews Support Unit (NIHR CRSU).
Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2021/11/18
Y1 - 2021/11/18
N2 - Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. Primary objective. To assess whether anticholinergic burden, as defined at the level of each individual scale, is a prognostic factor for further cognitive decline or neuropsychiatric disturbances in people with mild cognitive impairment (MCI) or dementia. Secondary objective. To compare the prognostic validity of different anticholinergic burden scales. To examine the effect of type of dementia and severity of dementia on the association between anticholinergic burden and rate of cognitive decline or neuropsychiatric disturbances. To examine the effect of setting (care home versus non-care home) on the association between anticholinergic burden and rate of cognitive decline or neuropsychiatric disturbances. To examine whether anticholinergic burden is a prognostic factor for other clinical outcomes in people with MCI or dementia.
AB - Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. Primary objective. To assess whether anticholinergic burden, as defined at the level of each individual scale, is a prognostic factor for further cognitive decline or neuropsychiatric disturbances in people with mild cognitive impairment (MCI) or dementia. Secondary objective. To compare the prognostic validity of different anticholinergic burden scales. To examine the effect of type of dementia and severity of dementia on the association between anticholinergic burden and rate of cognitive decline or neuropsychiatric disturbances. To examine the effect of setting (care home versus non-care home) on the association between anticholinergic burden and rate of cognitive decline or neuropsychiatric disturbances. To examine whether anticholinergic burden is a prognostic factor for other clinical outcomes in people with MCI or dementia.
UR - http://www.scopus.com/inward/record.url?scp=85119426742&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD015196
DO - 10.1002/14651858.CD015196
M3 - Article
AN - SCOPUS:85119426742
SN - 1465-1858
VL - 2021
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 11
M1 - CD015196
ER -